Non-invasive diagnosis of portal vein occlusion by radionuclide angiography

P MacMathuna, M K O'Connor, D G Weir, P W N Keeling

Abstract
The accuracy of non-invasive radionuclide angiography in detecting portal vein occlusion was assessed in 61 patients — 10 with portal vein occlusion confirmed by conventional portography, 25 with chronic liver disease and a patent portal vein (mild=12, severe=13), and 26 with normal liver function, who served as controls. The median percentage portal venous flow for the portal vein occlusion group was 6% (range 1–30) (consistent with negligible flow) compared with 78% (52–87) for control subjects (p<0.005) and 68% (61–80) and 49% (23–59) respectively for patients with mild and severe liver disease (p<0.001 and p<0.005). At a portal venous inflow of <20%, the procedure had a specificity of 100% and sensitivity of 90% in diagnosing portal vein occlusion. Non-invasive radionuclide angiography provides a safe and accurate screening method for evaluating portal vein patency or occlusion in the investigation of portal hypertension or before liver transplantation.

(Gut 1992; 33: 1671–1674)

Complete or partial occlusion of the portal vein is a common cause of portal hypertension in childhood.1,2 In adults, portal vein occlusion (PVO) may complicate chronic liver disease but more frequently results from intra-abdominal sepsis, neoplasia, or a thrombotic disorder.3 In many cases, however, no aetiologic factor is found. Gastrointestinal haemorrhage is the commonest clinical presentation, while the presence of ascites and encephalopathy usually indicate associated liver dysfunction. Early recognition of the condition is important since management may differ from that of cirrhosis, particularly if portacaval surgery is considered.4 PVO is a contraindication to liver transplantation and after transplantation, thrombosis of the portal vein (or hepatic artery) is a recognised cause of graft dysfunction.4 Consequently, defining the patency or occlusion of the portal venous system is equally important in pretransplant assessment and in post-transplant graft dysfunction.4

At present, the accurate diagnosis of PVO requires either arterial portography or splenoportography, both of which are invasive radiological procedures that may have complications, particularly in patients with a coagulopathy.6 A reliable non-invasive diagnostic technique would represent a considerable advance. Recent reports have advocated either ultrasonography7 or computer tomography.8 The application of radionuclide angiography in assessing portal vein patency or occlusion has received limited attention. We have previously described a new non-invasive dynamic hepatic scintigraphic technique to define the portal venous and hepatic arterial contributions to total liver perfusion.9 More recent in vivo animal studies provide experimental evidence to validate this technique.10 Preliminary use of this method in a small number of patients successfully detected PVO.10 The present study aimed to assess the accuracy of this technique in the diagnosis of PVO in a larger cohort of patients.

Patients and methods

PATIENTS
Three groups of patients were included in this investigation (Table I).

Group 1: patients with PVO (Table II)
Ten patients (5 men and 5 women) with a mean age of 47 years (range 21–72) were assessed. The diagnosis of PVO was confirmed in each case by

<table>
<thead>
<tr>
<th>Patient no</th>
<th>Age (years)</th>
<th>Aetiology</th>
<th>Cirrhosis</th>
<th>Clinical features</th>
<th>Diagnostic method</th>
<th>Cavernous transformation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>54</td>
<td>Idiopathic</td>
<td>No</td>
<td>Oesophageal varices</td>
<td>Angiography</td>
<td>No</td>
</tr>
<tr>
<td>2</td>
<td>21</td>
<td>Idiopathic</td>
<td>No</td>
<td>Oesophageal varices</td>
<td>Angiography</td>
<td>No</td>
</tr>
<tr>
<td>3</td>
<td>55</td>
<td>Pancreatitis</td>
<td>No</td>
<td>Oesophageal varices</td>
<td>Angiography</td>
<td>No</td>
</tr>
<tr>
<td>4</td>
<td>35</td>
<td>Idiopathic/ trauma</td>
<td>Yes</td>
<td>Oesophageal varices/hepatic encephalopathy</td>
<td>Angiography</td>
<td>No</td>
</tr>
<tr>
<td>5</td>
<td>63</td>
<td>Cirrhosis</td>
<td>Yes</td>
<td>Oesophageal varices/hepatic encephalopathy</td>
<td>Angiography</td>
<td>No</td>
</tr>
<tr>
<td>6</td>
<td>40</td>
<td>Polycythaemia rubra ve ra</td>
<td>No</td>
<td>Oesophageal varices/ascites</td>
<td>Angiography</td>
<td>No</td>
</tr>
<tr>
<td>7</td>
<td>69</td>
<td>Idiopathic</td>
<td>No</td>
<td>Oesophageal varices</td>
<td>Angiography</td>
<td>No</td>
</tr>
<tr>
<td>8</td>
<td>38</td>
<td>Idiopathic</td>
<td>Yes</td>
<td>Asymptomatic</td>
<td>Laparotomy + angiography</td>
<td>Yes</td>
</tr>
<tr>
<td>9</td>
<td>72</td>
<td>Cirrhosis/hepatocelellar carcinoma?</td>
<td>Yes</td>
<td>Oesophageal varices</td>
<td>Angiography</td>
<td>Yes</td>
</tr>
<tr>
<td>10</td>
<td>51</td>
<td>Idiopathic</td>
<td>No</td>
<td>Oesophageal varices</td>
<td>Angiography</td>
<td>Yes</td>
</tr>
</tbody>
</table>
conventional arterial portography or splenoportography with additional conclusive evidence from laparotomy and post mortem examination in two cases (see Table II). In three patients there was coexisting liver disease and in one of these patients (patient 9), the PVO was associated with the development of hepatocellular carcinoma. Pancreatitis (patient 3) and polycythaemia rubra vera (PRV) (patient 6), accounted for two other cases while no cause was evident in the remaining five patients (idiopathic).

**Group 2: patients with chronic liver disease without PVO**

This group comprised 25 patients (12 men and 13 women) with a mean age of 51 years (range 30–74), all of whom had documented chronic liver disease (clinical, biochemical, and histological criteria) with patent portal vein as shown radiologically. The aetiological factors for the liver disease included alcohol (n=19), chronic active hepatitis (n=3), Wilson’s disease (n=2), and haemochromatosis (n=1). Twenty of the patients had portal hypertension, shown by the presence of endoscopically proved oesophageal varices, with or without splenomegaly. The patients were classified according to the severity of liver disease using the modified Child’s-Pugh score into two groups: mild disease with a Child-Pugh score of <8 (n=12) and severe disease with a score of >8 (n=13).

**Group 3: normal control subjects**

There were 26 control subjects (14 men and 12 women) with a mean age of 54 years (range 25–78) none of whom had any clinical, biochemical, or radiological evidence of liver disease or extrahepatic portal hypertension. These patients were undergoing cardiac, bone, or cerebral isotope scanning and dynamic liver scintigraphy could be incorporated without unnecessary additional exposure to radionuclides.

Written informed consent was obtained from each patient before the study.

**METHODS**

The technique of dynamic hepatic radionuclide angiography has been described previously in detail. In brief, fasting patients were positioned supine beneath a large field of view gamma camera (General Electric, Maxi II). After a 5 minute resting period, in patients with PVO or liver disease, 370 MBq (10 mCi) of 99mTc pertechnetate were administered by bolus peripheral intravenous injection followed rapidly by a 30 ml saline flush to ensure rapid transit of the radionuclide into the heart. In control subjects, 555–740 MBq (15–20 mCi) of 99mTc labelled human albumin, methylene diphenosphonate, or glucoheptonate were administered in a similar manner. Computer image acquisition began at the onset of the injection. Images were acquired onto a 64 × 64 word matrix at a rate of 0·5 seconds/image for 100 seconds and stored on an A 2 computer system for subsequent analysis (Medical Data Systems, Ann Arbor, MI, USA). The procedure takes approximately 3 minutes to complete.

Preliminary data analysis involved a summation of the initial 30 images to form a composite image outlining the arterial phase of tracer transit through the hepatobiliary system. Regions of interest (ROIs) were drawn over the liver, spleen, lungs, and left kidney ensuring that the liver ROI excluded the descending aorta and right kidney (Fig 1). The ROIs were then used to generate time-activity curves (TACs). Because of interference from the right lung into the liver ROI, a correction factor was applied to take account of this ‘cross-talk’, resulting in a corrected liver TAC (Fig 1). Deconvolution analysis of the TACs was used to improve separation of the arterial and portal venous

---

**Figure 1:** Schematic outline illustrating the field of view of the gamma camera including regions of interest (ROIs) over the liver, spleen, lung, and left kidney.

**Figure 2:** Left: corrected liver and spleen curves. Centre: curves following deconvolution analysis. Right: magnitude of the upslope matches that of the liver curve. A5 and A6 represent the areas under the spleen and liver curves respectively.
phases of total liver blood flow. In addition, this method takes account of tracer recirculation and therefore allows analysis of the deconvoluted curves by area under the curve as a measure of blood flow. The liver, spleen, and left kidney TACs were deconvoluted with the lung curve using a modified fast Fourier transform technique as described by Juni et al. 11 If the assumption is made on an anatomical basis, that blood flow through the splenic artery has a similar pattern to hepatic arterial flow, then the splenic TAC can be used as a model for hepatic arterial flow. In order to compensate for differences in absolute flow and in attenuation by overlying tissues, the splenic TAC was multiplied by a constant so that the upslope of the splenic TAC overlies the early segment of the total liver TAC (Fig 2). Thus, the modified splenic TAC approximates to the hepatic arterial TAC. The liver and modified splenic TAC are then integrated to yield the areas under the curve, \( A_2 \) and \( A_3 \), respectively (Fig 2). The hepatic arterial component (\( \%HA\)) was calculated from the formula:

\[
\%HA = \frac{A_3}{A_L} \times 100
\]

and the portal venous component (\( \%PV\)) determined as:

\[
\%PV = 100 - \%HA.
\]

Recent in vivo experimental animal studies have validated this deconvolutional technique to define \( \%HA\) and \( \%PV\) by dynamic radionuclide angiography. 11 The results are expressed as \( \%HA\) and \( \%PV\) and are shown as median (range). Specificity and sensitivity values were calculated and statistical analysis was performed using the Mann-Whitney U test for non-parametric data. \( p<0.05\) was taken as the level of significance.

**Results**

Table III outlines the individual values for \( \%HA\) and \( \%PV\) in each of the 10 patients with PVO (group 1). The \( \%PV\) flow in group 1 was 8.6% (range 1–30), which reflects negligible portal venous inflow to the liver. When the three patients with coexisting cavernous transformation of the portal vein were excluded, the calculated \( \%PV\) was further reduced to 3% (range 1–10). Only the three patients with cavernous transformation had a \( \%PV\) flow of more than 10% (11%, 18%, and 30% respectively) (Table III).

Figure 3 illustrates the differences in \( \%PV\) flow between the patients with PVO and the two control groups (2 and 3). The \( \%PV\) flow for control subjects (group 3) was 78% (range, 53–86) which is consistent with known physiological estimates. 12 In group 2, a progressive reduction in the \( \%PV\) contribution with increasing severity of liver disease was observed, from 68% in patients with mild disease (range 61–80) \((p>0.10\,v\) controls) to 49% in the group with severe disease (range 22–61) \((p<0.001\,v\) controls). In two patients with decompensated cirrhosis (Child-Pugh score C12&13), the \( \%PV\) flow was 23% and 28%, respectively. The \( \%PV\) flow was significantly reduced in the PVO group when compared with both control groups 2 and 3 \((p<0.001\,v\) controls, \(p<0.001\,v\) mild, and \(p<0.005\,v\) severe liver disease (Fig 3)).

For a \( \%PV\) flow of 20% or less, the specificity and sensitivity of this procedure in accurately detecting PVO were 100% and 90%, respectively. At a \( \%PV\) flow of 30% or less, the specificity was reduced to 85% while the sensitivity increased to 100%.

**Discussion**

Confirmation of portal vein patency or occlusion relies predominantly upon venous phase arterial portography or splenoportography, both invasive and time consuming radiological procedures that may have complications. Several investigators have attempted to define the portal venous and hepatic arterial contributions to total liver blood flow by non-invasive means including ultrasound 13 and radionuclide angiography. 14–16 The degree of portasystemic shunting in cirrhosis has also been examined by scintigraphy, however per rectal administration of the radionuclide is required. 17 The present investigation is the first report of radionuclide angiography specifically used to assess the patency/occlusion of the portal venous system.

We have shown that the \( \%PV\) flow in all the patients with PVO was 8.6% with a range of 1 to 30%, indicating that blood flow to the liver may become almost entirely dependant upon the

**Table III** Individual results of the hepatic arterial (\( \%HA\)) and portal venous (\( \%PV\)) flow for the 10 patients with portal venous occlusion

<table>
<thead>
<tr>
<th>Patient no</th>
<th>( %HA)</th>
<th>( %PV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>98</td>
<td>2</td>
</tr>
<tr>
<td>2</td>
<td>92</td>
<td>8</td>
</tr>
<tr>
<td>3</td>
<td>98</td>
<td>2</td>
</tr>
<tr>
<td>4</td>
<td>97</td>
<td>3</td>
</tr>
<tr>
<td>5</td>
<td>99</td>
<td>1</td>
</tr>
<tr>
<td>6</td>
<td>90</td>
<td>10</td>
</tr>
<tr>
<td>7</td>
<td>99</td>
<td>1</td>
</tr>
<tr>
<td>Mean (patients 1–7)</td>
<td>96.4</td>
<td>3.6</td>
</tr>
<tr>
<td>8*</td>
<td>70</td>
<td>30</td>
</tr>
<tr>
<td>9*</td>
<td>89</td>
<td>11</td>
</tr>
<tr>
<td>10*</td>
<td>82</td>
<td>18</td>
</tr>
<tr>
<td>Mean (patients 1–10)</td>
<td>91.4</td>
<td>8.6</td>
</tr>
</tbody>
</table>

*These patients also had cavernous transformation of the portal vein.
hepatic artery. Furthermore, when the patients with cavernous transformation are excluded, the observed portal venous input to the liver becomes negligible (<3%). Defining occlusion of the portal vein as a % PV flow of 20% or less, the technique is highly specific and sensitive. The results indicate therefore that this radionuclide technique accurately detects occlusion to portal venous inflow to the liver, particularly in patients without coexisting cavernous transformation. Another report also demonstrated the absence of any significant portal venous flow in two patients in whom portal vein thrombosis was subsequently confirmed at necropsy.16

There are two circumstances that may potentially reduce the diagnostic accuracy of this technique. Firstly, the presence of a cavernous transformation or ‘cavernoma’ represents the development of multiple periportal collateral channels in order to bypass the obstruction within the portal vein. Consequently, this provides a potential route for portal venous blood to reach the liver. The % PV flow observed in the three patients with cavernous transformation included in the present study ranged from 11% up to 30%. In these circumstances, the sensitivity of this method of detecting portal vein occlusion may be diminished. Nevertheless, only one patient with documented PVO in the present study had a % PV flow of greater than 20%.

Secondly, a major reduction in portal venous inflow to the liver associated with reversed (causal) blood flow, may occur in the absence of obstruction within the portal venous system, as observed in two of the patients with decompensated alcoholic cirrhosis with % PV flows of 28% and 23% respectively (Fig 3). Consequently, % PV flow values of between 20 and 30% fall within what might be termed a diagnostic ‘grey area’. It seems appropriate at the present time, therefore, that the suspicion of PVO, particularly in patients with decompensated liver disease as indicated by the presence of an appreciably reduced portal blood flow, needs to be confirmed by conventional arterial portography. Nevertheless, at a % PV flow of below 20%, radionuclide angiography allowed a clear distinction to be made between patients with a patent and obstructed portal venous system.

In conclusion, this study shows that non-invasive radionuclide angiography is of benefit in screening for obstruction within the portal vein as part of the preliminary investigation of portal hypertension and chronic liver disease or during the assessment for liver transplantation. This method may also be helpful in confirming the patency/occlusion of a portacaval shunt. The procedure is safe and inexpensive. Further evaluation of radionuclide angiography in comparison with other non-invasive methods (ultrasound, computed tomography, and nuclear magnetic resonance) and conventional arterial portography merits consideration.

Preliminary results of this study were presented to British Society of Gastroenterology meeting, September 1988 and published in abstract form in Gut 1988; 29: A1461.

Non-invasive diagnosis of portal vein occlusion by radionuclide angiography.

P MacMathuna, M K O'Connor, D G Weir and P W Keeling

Gut 1992 33: 1671-1674
doi: 10.1136/gut.33.12.1671

Updated information and services can be found at:
http://gut.bmj.com/content/33/12/1671

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/